Ibrutinib
(asked on 22nd June 2018) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans he has to fund patient access to Ibrutinib.
This question was answered on 28th June 2018
NHS England has advised that, since January 2017, it has commissioned ibrutinib for relapsed / refractory chronic lymphocytic leukaemia and chronic lymphocytic leukaemia with 17p deletion or TP53 mutation. Prior to this, ibrutinib was funded via the Cancer Drugs Fund.
NHS England is currently reviewing its treatment criteria for ibrutinib and is willing to receive, by the end of July 2018, any further evidence that patients and clinicians may wish to submit on this matter.